1. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer 
Chee-Seng Tan, MRCP, David Gilligan, FRCPE, Dr Simon Pacey, FRCP 
The Lancet Oncology 
Volume 16, Issue 9, Pages e447-e459 (September 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure
Timeline in understanding the biology and therapeutic targeting of EGFR-mutant lung cancer
EMT=epithelial to mesenchymal transition. SCLC=small-cell lung cancer. MET=mesenchymal to epithelial transition. CTC=circulating tumour cell. ctDNA=circulating tumour DNA.
The Lancet Oncology  , e447-e459DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions